About RYAH Group, Inc.
RYAH Group, Inc. (‘RYAH’) is a connected device and big data and technology company focused on valuable predictive analysis in the global medical plant and nutraceutical intake industry. Its robust artificial intelligence platform aggregates and correlates HIPAA-compliant patient data, which is intended to help doctors and patients personalize plant-based treatments to better predict treatment outcomes. The data collection is relevant for clinics, doctors, dispensaries and pharmaceutical companies and Licensed Processors (LPs) to monitor and manage formulation effects on patient and demographics. With a strong IP portfolio, RYAH gathers deep and insightful data on the complete patient session and formulation lifecycle.
An FMA investigation into the cannabis business was one, but not the only, issue.
Controversial medical cannabis company Medical Kiwi has been barred from listing on the NZX, with an active FMA investigation into the company playing a part in the decision.
Nelson-based Medical Kiwi was founded and chaired by former Nelson mayor Aldo Miccio and planned on operating a vertically integrated seed-to-sale medical cannabis business.
NZ RegCo chief executive Joost van Amelsfort said a determination had been made to not proceed with Medical Kiwi’s direct listing application.
“NZ RegCo confirms it sought [general] information from the FMA on the nature and status of the FMA’s inquiries into Medical Kiwi’s August 2020 crowdfunding capital
Medicinal cannabis company Medical Kiwi denied listing on NZX stuff.co.nz - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from stuff.co.nz Daily Mail and Mail on Sunday newspapers.
Cannabis company Medical Kiwi declined NZX listing
9 Apr, 2021 01:00 AM
6 minutes to read
Medical Kiwi has been denied a listing on the NZX. Photo / 123RF
Cannabis company Medical Kiwi - the subject of ongoing inquiries by the financial markets regulator - has been denied a listing on the NZX. NZ RegCo chief executive, Joost van Amelsfort, responsible for NZX regulation, confirmed the stock exchange has declined Medical Kiwi s application and determined the company is not suitable for a direct listing at this time.
A Financial Markets Authority (FMA) spokesman said its investigations into the company are ongoing.
Medical Kiwi s chairman and executive director, Aldo Miccio, rejected the characterisation that his firm s application has been declined.